Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMKK2 | Q96RR4 | 2/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.37 |
| ▸ | BRD4 | O60885 | 2/20 | 0.35 |
| ▸ | BRAF | P15056 | 2/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | AXL | P30530 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2890696 | 0.86 | BRAF (0.43) | CAMKK2RIPK1BRD4BRAFJAK2 | |
| SCHEMBL3505623 | 0.86 | BRAF (0.44) | CAMKK2RIPK1BRD4BRAFCLK1 | |
| SCHEMBL3706480 | 0.85 | BRD4 (0.37) | RIPK1BRD4BRAFCLK1DYRK1A | |
| SCHEMBL3504298 | 0.84 | BRAF (0.35) | CAMKK2RIPK1BRD4BRAFJAK2 | |
| SCHEMBL3707346 | 0.83 | AXL (0.52) | CAMKK2RIPK1JAK3DYRK1AAURKA | |
| SCHEMBL2898883 | 0.83 | CYP3A4 (0.44) | CAMKK2JAK2JAK3AXL | |
| SCHEMBL3505504 | 0.83 | MTNR1A (0.40) | CAMKK2CLK1DYRK1AAXL | |
| SCHEMBL3505863 | 0.82 | BRAF (0.44) | CAMKK2BRAFCLK1DYRK1AAXL | |
| SCHEMBL3508004 | 0.82 | BRAF (0.33) | CAMKK2RIPK1BRD4BRAFJAK2 | |
| SCHEMBL3700070 | 0.82 | RPS6KB1 (0.39) | RPS6KB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CAMKK2 497/4885RIPK1 637/4885BRD4 2367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.